Browse Studies — Arctuva

Phase 2

A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety and Tolerability of Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis

The purpose of this study is to evaluate efficacy, safety and tolerability of s.c. ianalumab administered in participants with diffuse cutaneous systemic scler…

Diffuse Cutaneous Systemic Sclerosis

Estimated

~$10 – $8,750

Novartis PharmaceuticalsNCT06470048

Phase 2

A Phase 2 Randomized, Double-blind, Placebo-Controlled Study to Assess the Safety and Efficacy of MTX-474 in the Treatment of Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)

A Phase 2 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-474 in Participants with Diffuse Cutaneous Systemic Sclerosis (d…

Diffuse Cutaneous Systemic Sclerosis

Estimated

~$10 – $8,750

Mediar TherapeuticsNCT07287670

Phase 1

A Phase 1 Dose Evaluation Study of the Safety and Preliminary Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX112) in Adult Subjects With Refractory Autoimmune Disease

This is a single-arm, open-label, multicenter, ascending dose Phase 1 study evaluating the safety and preliminary efficacy of CTX112 in adult subjects with ref…

SLE (Systemic Lupus)Lupus Erythematosus, SystemicLupus Nephritis+4 more

Estimated

~$10 – $8,750

CRISPR TherapeuticsNCT06925542

Phase 1

A Phase I Multicohort Trial of Zamtocabtagene Autoleucel (Zamto-Cel) in Subjects With Severe Refractory Autoimmune Diseases

AID is a phase I multi-cohort study to assess the safety and tolerability of zamtocabtagene autoleucel (zamto-cel) in patients with refractory autoimmune disea…

Lupus NephritisSystemic Lupus ErythematosusSystemic Sclerosis (SSc)+1 more

Estimated

~$10 – $8,750

Miltenyi Biomedicine GmbHNCT06708845